FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending August 2009
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
Financial Services Authority
GlaxoSmithKline plc received on 21 August 2009 from Legal & General Group plc a notification of interests in GlaxoSmithKline plc Ordinary shares of 25 pence each, dated on 19 August 2009. This notice is given in accordance with DTR 5.8.12. |
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES |
||||
1. Identity of the issuer or the underlying issuer |
GlaxoSmithKline Plc |
|||
2. Reason for the notification (please tick the appropriate box or boxes): |
||||
An acquisition or disposal of voting rights |
Yes |
|||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached. |
||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
||||
An event changing the breakdown of voting rights |
||||
Other (please specify): |
||||
3. Full name of person(s) subject to the |
Legal & General Group Plc (Group) |
|||
4. Full name of shareholder(s) |
Legal & General Assurance (Pensions Management) Limited (PMC) |
|||
5. Date of the transaction and date on |
19 August 2009 |
|||
6. Date on which issuer notified: |
21 August 2009 |
|||
7. Threshold(s) that is/are crossed or |
Below 5% (Group) |
8. Notified details: |
||||||||||||||||
A: Voting rights attached to shares |
||||||||||||||||
Class/type of |
Situation previous |
Resulting situation after the triggering transaction |
||||||||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights |
||||||||||||
Direct |
Indirect |
Direct |
Indirect |
|||||||||||||
ORD |
260,231,752 |
260,231,752 |
Below 5% |
|||||||||||||
B: Qualifying Financial Instruments |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Exercise price |
Expiration date |
Exercise/ |
Number of voting rights instrument refers to |
% of voting rights |
|||||||||||
Nominal |
Delta |
|||||||||||||||
Total (A+B+C) |
||||||||||||||||
Number of voting rights |
Percentage of voting rights |
|||||||||||||||
Below 5% |
9. Chain of controlled undertakings through which the voting rights and/or the |
||
Legal & General Group Plc (Direct and Indirect) (Group) (Below 5%) Legal & General Group Plc (Direct) (L&G) (234,245,526 – 4.51% = LGAS, LGPL & PMC) Legal & General Investment Management (Holdings) Legal & General Insurance Holdings Limited (LGPL) |
||
Proxy Voting: |
||
10. Name of the proxy holder: |
N/A |
|
11. Number of voting rights proxy holder will cease |
N/A |
|
12. Date on which proxy holder will cease to hold |
N/A |
|
13. Additional information: |
Notification using the total voting rights figure of 5,188,446,713 |
|
14. Contact name: |
Helen Lewis (LGIM) |
|
15. Contact telephone number: |
020 3124 3851 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: August 21 2009
By: VICTORIA WHYTE
------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc